Medical City’s Dallas Valve Institute became the first U.S. hospital to perform a Food and Drug Administration (FDA) commercially-approved heart procedure that, until now, had been approved only for patients in clinical trials. The procedure is known as Transcatheter Aortic Valve Replacement (TAVR), which we’ve talked about before on this blog.

Dr. Todd Dewey, Surgical Director aof Heart Transplant and Structural Heart Disease,  and Dr. Bruce Bowers, Medical Director for Invasive Cardiology and Co-Director of the Dallas Valve Institute conducted the procedure.  “This approach provides new hope to thousands of patients with aortic stenosis, who had been told they were out of options,” said Dr. Bowers. “We look forward to making it possible for hundreds of patients to now see children marry, grandchildren born, and golden anniversaries celebrated.”

The patient, a 72 year old female, is doing well. Dr’s used the transapical approach in which a tube containing an Edwards SAPIEN valve is inserted through a tiny incision between the ribs and guided into place in the heart, replacing the diseased aortic valve. The transfemoral approach was approved by the FDA in November of 2011 for commercial use, for patients who are too weak to survive open-heart surgery. The transapical approach approved for commercial use provides a new option for previously inoperable patients whose deteriorating leg arteries make the transfemoral approach difficult or impossible.

For more information on the Dallas Valve Institute and TAVR, visit